Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.

Bakris G, Briasoulis A, Dahlof B, Jamerson K, Weber MA, Kelly RY, Hester A, Hua T, Zappe D, Pitt B; ACCOMPLISH Investigators.

Am J Cardiol. 2013 Jul 15;112(2):255-9. doi: 10.1016/j.amjcard.2013.03.026. Epub 2013 Apr 11.

PMID:
23582626
3.

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA; ACCOMPLISH Trial investigators.

Lancet. 2010 Apr 3;375(9721):1173-81. doi: 10.1016/S0140-6736(09)62100-0. Epub 2010 Feb 18.

PMID:
20170948
4.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators.

N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.

5.

Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.

Skoglund PH, Svensson P, Asp J, Dahlöf B, Kjeldsen SE, Jamerson KA, Weber MA, Jia Y, Zappe DH, Östergren J; ACCOMPLISH investigators.

J Clin Hypertens (Greenwich). 2015 Feb;17(2):141-6. doi: 10.1111/jch.12460. Epub 2014 Dec 22.

7.

Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.

Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ, Hua TA, Kelly RY, Zappe D, Hester A, Tuomilehto J, Ostergren J, Ibsen H, Weber M; Avoiding Cardiovascular Events Through Combination Therapy In Patients Living With Systolic Hypertension (ACCOMPLISH).

Blood Press. 2012 Apr;21(2):82-7. doi: 10.3109/08037051.2011.598699. Epub 2011 Aug 10.

PMID:
21830844
8.

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.

Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.

Clin Ther. 2007 Feb;29(2):279-89.

PMID:
17472820
9.

Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.

Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B.

Lancet. 2013 Feb 16;381(9866):537-45. doi: 10.1016/S0140-6736(12)61343-9. Epub 2012 Dec 6.

PMID:
23219284
11.
12.
13.

The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.

Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E, Staikos-Byrne L, Shi V, Jamerson K; ACCOMPLISH Investigators.

J Cardiometab Syndr. 2008 Fall;3(4):229-33. doi: 10.1111/j.1559-4572.2008.00023.x.

14.

Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.

Kereiakes DJ, Neutel JM, Punzi HA, Xu J, Lipka LJ, Dubiel R.

Am J Cardiovasc Drugs. 2007;7(5):361-72.

PMID:
17953475
15.

Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.

Weber MA, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J, Lefkowitz M, Hester A, Shi V, Weir M, Kjeldsen S, Massie B, Nesbitt S, Ofili E, Jamerson K.

Blood Press. 2007;16(1):13-9.

PMID:
17453747
16.

Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.

Chrysant SG, Littlejohn T 3rd, Izzo JL Jr, Kereiakes DJ, Oparil S, Melino M, Lee J, Fernandez V, Heyrman R.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):233-43. doi: 10.2165/11634160-000000000-00000.

PMID:
22799613
17.

[Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].

Fan CM, Yan LR, Tao YK, Wang L, Li YQ, Gao MM, Wang YN, Li CX, Wang XW, Lu XL, Pang HM, Li YS.

Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jan;39(1):57-60. Chinese.

PMID:
21418799
18.

Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.

Lacourcière Y, Wright JT Jr, Samuel R, Zappe D, Purkayastha D, Black HR; EVALUATE study.

Blood Press Monit. 2009 Jun;14(3):112-20. doi: 10.1097/MBP.0b013e32832a9da7.

PMID:
19384192
19.

Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).

Yamaguchi J, Hagiwara N, Ogawa H, Koyanagi R, Kasanuki H, Takagi A, Mori F, Nagashima M, Yagi M; HIJ-CREATE Investigators.

Am J Cardiol. 2010 Sep 15;106(6):819-24. doi: 10.1016/j.amjcard.2010.05.007. Epub 2010 Aug 2.

PMID:
20816122
20.

Supplemental Content

Support Center